Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Merck & Co.

Request full access

Merck develops and produces medicines, vaccines, biologic therapies and animal health products

Rahway, United StatesFounded 1891Biotech & Life Sciences

About Merck & Co.

Merck & Co., Inc., headquartered in Kenilworth, N.J., is a global healthcare company dedicated to following the science to tackle some of the world's greatest health threats. The company focuses on developing innovative medicines and vaccines for a wide range of health issues, including cardiovascular disease, diabetes, and cancer. Merck serves a diverse clientele, including patients, healthcare professionals, and institutions worldwide. Operating in the pharmaceutical and biotechnology markets, Merck's business model revolves around extensive research and development (R&D) to create new treatments and therapies. The company generates revenue primarily through the sale of prescription medicines, vaccines, and animal health products. Additionally, Merck offers patient assistance programs to provide free medicines and vaccines to qualified patients, and professional resources through platforms like Merck Connect and Merck Manuals.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 1983
Employees
44,700
Open positions
789
Dealroom signal
29.8/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology, Medical Devices, Health Platform
Sector
Personal Health, Diabetes, Risk Management, Developer Tools, Biotechnology, Oncology
Business model
Manufacturing
Client focus
B2B, B2C
Investment activity
69 companies, latest May 2026
Capital deployed
$969M
Preferred round
ACQUISITION

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO DEBT✓Debt Dec 2025 $2B — Undisclosed ↗
POST IPO DEBT✓Debt Sep 2025 $6B — Undisclosed ↗
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

Merck & Co. website traffic

Latest recorded traffic for Merck & Co. is 1M monthly website visits, up 25% over the last three months. Merck & Co.'s team declined 42.7% over the past year.

Latest monthly visits1M 3-month web change+25% 1-year team growth-42.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Terns PharmaceuticalsFoster City, United StatesBiopharmaceutical company focused on discovering therapies that will improve the global disease burden $6.7Bvaluation Cidara TherapeuticsSan Diego, United StatesCidara Therapeutics is developing innovative therapies $9.2Bvaluation Solve TherapeuticsSan Diego, United StatesTargeted cancer therapies enhancing safety and precision $480Mvaluation Meta-fluxDublin, IrelandMeta-flux is an AI biologist for pharmaceutical drug development. $7.9Mvaluation Verona PharmaLondon, United KingdomFirst-in-class inhaled therapies for chronic respiratory diseases $10Bvaluation EkincareGafoornagar, IndiaA corporate health benefits platform $60Mvaluation HDBangkok, ThailandProviding affordable healthcare and surgeries in southeast asia $31Mvaluation Ambrosia BiosciencesBoulder, United StatesSmall molecule therapies for obesity and metabolic disorders, delivered orally $400Mvaluation PersonalisMenlo Park, United StatesContract research organization and genome-scale diagnostics services company specializing in genome guided medicine $1.6Bvaluation Modifi BiosciencesNew Haven, United StatesAt Modifi Bio, we are changing the oncology treatment paradigm by developing therapeutics that uniquely target specific acquired cancer cell DNA mutations $17Mvaluation Ash WellnessNew York City, United StatesPowered by Ash - Modern At-Home Diagnostics Delfi DiagnosticsBaltimore, United StatesDetects cancer early, when it is most curable, using high precision non-invasive blood tests $900Mvaluation

Merck & Co. in the Rahway ecosystem

Live from Dealroom

The Merck & Co. office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • HHS Administration for Strategic Preparedness and Response

Series B and later2 investors entered at this stage

  • Scissortail Wealth Management
  • Wealth Management Partners

Other known investors2 additional known investors

  • ARCH Venture Partners
  • US Biomedical Advanced Research and Development Authority
Team profiled 1,363 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Rahway HQ
Book a demo for the full country breakdown

See Merck & Co.’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.